Global Peptic Ulcer Drugs Market 2014-2018

About Peptic Ulcer and Drugs Used for the Treatment
A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer.

TechNavio's analysts forecast the Global Peptic Ulcer Drugs market to grow at a CAGR of 2.9 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Peptic Ulcer Drugs market for the period 2014–2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of peptic ulcers that are available in the market.
TechNavio's report, the Global Peptic Ulcer Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Peptic Ulcer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ EMEA
‧ APAC
Key Vendors
‧ AstraZeneca plc
‧ Eisai Co. Ltd.
‧ Daewoong Pharmaceutical Co. Ltd.
‧ Takeda Pharmaceutical Co. Ltd.
Other Prominent Vendors

‧ Daiichi Sankyo
‧ Dr. Reddy's Laboratories
‧ Eumedica
‧ Ferring Pharmaceuticals
‧ Horizon Pharma
‧ Johnson and Johnson
‧ Merck Sharp and Dohme
‧ Otsuka Holdings
‧ Pfizer
‧ PharmaKing
‧ Pozen
‧ Rottapharm Madaus
‧ Taiho Pharmaceutical
‧ Zeria Pharmaceutical
‧ Zuventus Healthcare
Market Driver
‧ Increased Incidence of H. pylori Infections.
‧ For a full, detailed list, view our report.
Market Challenge
‧ Adverse Effect of PPIs.
‧ For a full, detailed list, view our report.
Market Trend
‧ Use of Combination Drugs.
‧ For a full, detailed list, view our report.
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Nexium
04.1.2 Losec
04.1.3 Vimovo
04.1.4 Pariet
04.1.5 Selbex
04.1.6 Albis
04.1.7 Lanpra/ Prevacid
04.1.8 Dexilant
04.1.9 Takelda
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Pipeline Portfolio
08.1 Key Information for the Pipeline Candidates
08.1.1 PA32540
08.1.2 TAK-438
08.1.3 Lafutidine
08.1.4 D961H
08.1.5 PMK-S005
08.1.6 YF476
09. Market Segmentation by Class of Drugs
09.1 Proton Pump Inhibitors
09.2 H2 Receptor Antagonists
09.3 Gastric Mucosal Protective Drugs
09.4 Antacids
09.5 Antibiotics
09.6 Prostaglandin Agonists
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors & Expected Future Vendors
19. Key Vendor Analysis
19.1 AstraZeneca plc
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Revenue by Business Segmentation
19.1.6 Revenue Comparison 2011-2013
19.1.7 Sales Revenue by Geographical Segmentation
19.1.8 Key Developments
19.1.9 SWOT Analysis
19.1.10 Strengths
19.1.11 Weaknesses
19.1.12 Opportunities
19.1.13 Threats
19.2 Daewoong Pharmaceutical
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation by Revenue 2013
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Geographical Segmentation by Revenue 2013
19.2.6 Business Strategy
19.2.7 Recent Developments
19.2.8 SWOT Analysis
19.2.9 Strengths
19.2.10 Weaknesses
19.2.11 Opportunities
19.2.12 Threats
19.3 Eisai Co
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Comparison between Revenue, Operating Income, and Net Income
19.3.4 Sales by Geography
19.3.5 Business Strategy
19.3.6 Key Information
19.3.7 SWOT Analysis
19.3.8 Strengths
19.3.9 Weaknesses
19.3.10 Opportunities
19.3.11 Threats
19.4 Takeda Pharmaceuticals
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Business Segmentation by Revenue 2013
19.4.5 Geographical Segmentation by Revenue 2013
19.4.6 Business Strategy
19.4.7 Recent Developments
19.4.8 SWOT Analysis
19.4.9 Strengths
19.4.10 Weakness
19.4.11 Opportunities
19.4.12 Threats
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Peptic Ulcer Drugs market 2013-2018 (in US$ million)
Exhibit 3: Snapshot of Pipeline Drugs 2013
Exhibit 4: Global Peptic Ulcer Drugs Market Segmentation by Class of Drugs
Exhibit 5: Global Peptic Ulcer Drugs Market Segmentation by Class of Drugs 2013
Exhibit 6: Global Peptic Ulcer Drugs market by Geographical Segmentation
Exhibit 7: Global Peptic Ulcer Drugs Market Share Analysis 2013
Exhibit 8: Sales Comparison of AstraZeneca's Peptic Ulcer Drugs 2011-2013 (US$ million)
Exhibit 9: Sales of Nexium for the Period of 2008-2013 (US$ million)
Exhibit 10: Sales of Losec for the Period 2009-2013 (US$ million)
Exhibit 11: US Sales of Dexilant for the period 2009-2012 (US$ million)
Exhibit 12: Sales of Prevacid 2009-2012 (US$ million)
Exhibit 13: Sales of Pariet in Various Geographies in 2013 (US$ million)
Exhibit 14: AstraZeneca: Business Segmentation
Exhibit 15: AstraZeneca: Revenue by Business Segmentation 2013
Exhibit 16: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 17: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
Exhibit 18: Daewoong Pharmaceutical: Business Segmentation by Revenue 2013
Exhibit 19: Daewoong Pharmaceutical: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 20: Daewoong Pharmaceutical: Geographical Segmentation by Revenue 2013
Exhibit 21: Eisai: Comparison between Revenue, Operating Income, and Net Income 2011-2013 (US$ billion)
Exhibit 22: Eisai: Sales by Geography 2013 (US$ billion)
Exhibit 23: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
Exhibit 24: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
Exhibit 25: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013